ITCI - イントラセルラ―・セラピ―ズ (Intra-Cellular Therapies Inc.) イントラセルラ―・セラピ―ズ

 ITCIのチャート


 ITCIの企業情報

symbol ITCI
会社名 Intra-Cellular Therapies Inc (イントラセルラ―・セラピ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イントラ・セルラー・セラピーズ(Intra-Cellular Therapies Inc.)はバイオ医薬品会社である。同社は中枢神経系(CNS)内の細胞内シグナル伝達機構を標的とすることにより、神経精神医学的および神経学的障害における不十分な医学的ニーズに対処する小分子薬物の発見・臨床開発を行う。同社は神経学的および精神医学的障害の治療のための薬物を発見・開発する。ルマテペロン(ITI-007)は、主要製品候補である。同社の双極性うつ病プログラムは、2つの第III相多施設、無作為化、二重盲検、プラセボ対照臨床試験で構成される。1つは単独治療としてルテテペロンを評価し、もう1つはリチウムまたはバルプロエートによる補助療法としてルテテペロンを評価する。同社は、アルツハイマー病(AD)を含む認知症患者の激越の治療のためのルテテペロンの第III相開発を開始した。   イントラセルラ―・セラピ―ズは、米国のバイオ製薬企業。中枢神経系内の細胞内シグナル伝達機構を標的とする神経精神障害および神経障害に対処する小分子薬の発見と臨床開発に焦点を当てる。主要製品候補は、統合失調症のためのファ―ストインクラスの治療薬「ITI-007」、統合失調症および認知障害の治療薬「 ITI-002」がある。   
本社所在地 430 East 29th Street New York NY 10016 USA
代表者氏名 Lawrence J. Hineline ローレンスJ.ヒネリン
代表者役職名 Chief Financial Officer Vice President - Finance Treasurer Assistant Secretary
電話番号 +1 212-923-3344
設立年月日 41122
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 49人
url www.intracellulartherapies.com
nasdaq_url https://www.nasdaq.com/symbol/itci
adr_tso
EBITDA EBITDA(百万ドル) -132.42960
終値(lastsale) 18.42
時価総額(marketcap) 1007744790.24
時価総額 時価総額(百万ドル) 996.25590
売上高 売上高(百万ドル) 0.03581
企業価値(EV) 企業価値(EV)(百万ドル) 592.49140
当期純利益 当期純利益(百万ドル) -127.03560
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intra-Cellular Therapies Inc revenues decreased from $210K to $0K. Net loss increased 63% to $72.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 91% to $59.3M (expense) General and administrative - Balancing v increase of 20% to $8.3M (expense).

 ITCIのテクニカル分析


 ITCIのニュース

   RBC Capital Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/04/12 01:46:54 Investing.com
RBC Capital Stick to Their Buy Rating for Intra-Cellular Therapies
   Leerink Partners Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/03/02 14:48:43 Investing.com
Leerink Partners Stick to Their Buy Rating for Intra-Cellular Therapies
   Intra-Cellular Therapies (NASDAQ:ITCI) Posts Earnings Results, Beats Estimates By $0.09 EPS  2021/02/27 17:22:55 Transcript Daily
Intra-Cellular Therapies (NASDAQ:ITCI) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09, MarketWatch Earnings reports. Intra-Cellular Therapies had a negative net margin of 1,985.32% and a negative return on equity of 48.27%. Shares of ITCI stock traded down […]
   Canaccord Genuity Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/02/26 11:37:03 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Intra-Cellular Therapies
   Mark Neumann Sells 5,184 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock  2021/02/25 10:44:41 Watchlist News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Mark Neumann sold 5,184 shares of the company’s stock in a transaction dated Friday, February 19th. The shares were sold at an average price of $39.22, for a total transaction of $203,316.48. Following the completion of the transaction, the executive vice president now owns 50,523 shares in the company, valued […]
   Leerink Partners Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/03/02 14:48:43 Investing.com
Leerink Partners Stick to Their Buy Rating for Intra-Cellular Therapies
   Intra-Cellular Therapies (NASDAQ:ITCI) Posts Earnings Results, Beats Estimates By $0.09 EPS  2021/02/27 17:22:55 Transcript Daily
Intra-Cellular Therapies (NASDAQ:ITCI) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09, MarketWatch Earnings reports. Intra-Cellular Therapies had a negative net margin of 1,985.32% and a negative return on equity of 48.27%. Shares of ITCI stock traded down […]
   Canaccord Genuity Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/02/26 11:37:03 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Intra-Cellular Therapies
   Mark Neumann Sells 5,184 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock  2021/02/25 10:44:41 Watchlist News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Mark Neumann sold 5,184 shares of the company’s stock in a transaction dated Friday, February 19th. The shares were sold at an average price of $39.22, for a total transaction of $203,316.48. Following the completion of the transaction, the executive vice president now owns 50,523 shares in the company, valued […]
   Intra-Cellular Therapies Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/24 16:13:00 Stock Market Daily
Intra-Cellular Therapies announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs  2021/02/04 12:21:57 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Arcus Biosciences Inc (NYSE: RCUS ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) BioVie Inc (NASDAQ: BIVI ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cassava Sciences Inc (NASDAQ: SAVA ) Castle Biosciences Inc (NASDAQ: CSTL ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) CorMedix Inc. Common Stock (NASDAQ: CRMD ) F-Star Therapeutics Inc (NASDAQ: FSTX ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Glaukos Corp (NYSE: GKOS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) ( announced a deal to be bought by Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) for $7.2 billion) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Immunome Inc (NASDAQ: IMNM ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) Jounce Therapeutics Inc (NASDAQ: JNCE ) MannKind Corporation (NASDAQ: MNKD ) Morphic Holding Inc (NASDAQ: MORF ) Myriad Genetics, Inc.
   RBC Capital Stick to Their Buy Rating for Intra-Cellular Therapies By Investing.com  2021/01/14 09:09:33 Investing.com
RBC Capital Stick to Their Buy Rating for Intra-Cellular Therapies

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イントラセルラ―・セラピ―ズ ITCI Intra-Cellular Therapies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)